10-Q 1 mrus-20220930.htm 10-Q 10-Q
20220001651311falseQ300-0000000--12-310001651311us-gaap:TaxAndCustomsAdministrationNetherlandsMembersrt:MinimumMember2022-01-012022-09-300001651311us-gaap:AdditionalPaidInCapitalMember2022-03-310001651311mrus:OtherMemberus-gaap:AccountsReceivableMember2022-01-012022-09-300001651311mrus:IncyteMember2021-01-012021-09-300001651311us-gaap:RetainedEarningsMember2022-01-012022-03-310001651311us-gaap:CommonStockMember2021-12-310001651311us-gaap:RetainedEarningsMember2022-09-300001651311mrus:UnbilledReceivablesMembermrus:IncyteMember2022-01-012022-09-300001651311mrus:CollaborationRevenueRelatedPartyMember2022-07-012022-09-300001651311us-gaap:AdditionalPaidInCapitalMember2021-07-012021-09-300001651311us-gaap:USTreasurySecuritiesMember2021-12-310001651311us-gaap:RetainedEarningsMember2022-03-310001651311mrus:IncyteCollaborationAndLicenseAgreementMembersrt:MaximumMember2022-01-012022-01-310001651311mrus:OfficeAndLaboratoryMembermrus:KadansSciencePartnerXIIBVMember2022-04-300001651311us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001651311us-gaap:AdditionalPaidInCapitalMember2021-03-310001651311mrus:LillyMembermrus:UnbilledReceivablesMember2022-09-300001651311mrus:OtherMember2022-01-012022-09-300001651311us-gaap:RetainedEarningsMember2021-06-300001651311mrus:DeferredRevenueMembermrus:CollaborationAgreementMember2021-12-310001651311mrus:OfficeAndLaboratoryMembersrt:MinimumMembermrus:KadansSciencePartnerXIIBVMember2022-04-012022-04-300001651311us-gaap:CommonStockMember2022-03-310001651311mrus:OfficeAndLaboratoryMembermrus:KadansSciencePartnerXIIBVMember2022-01-012022-09-300001651311us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-300001651311mrus:CollaborationAgreementMember2022-01-012022-09-300001651311mrus:IncyteMember2022-07-012022-09-300001651311us-gaap:PostemploymentRetirementBenefitsMember2020-04-012020-04-300001651311mrus:MarketableSecuritiesCurrentMember2022-09-300001651311mrus:MerusNVMembersrt:MaximumMembermrus:IncyteMember2022-09-300001651311mrus:LillyMember2021-01-012021-09-300001651311us-gaap:CommonStockMember2021-03-310001651311us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-310001651311mrus:LillyMember2022-01-012022-09-300001651311us-gaap:AccountsReceivableMembermrus:CollaborationAgreementMember2022-01-012022-09-300001651311srt:MaximumMembermrus:SalesAgreementMember2021-05-012021-05-310001651311mrus:CollaborationRevenueMember2021-07-012021-09-300001651311us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-09-300001651311mrus:CollaborationRevenueRelatedPartyMember2021-07-012021-09-3000016513112022-01-012022-03-310001651311mrus:CollaborationRevenueMember2022-07-012022-09-3000016513112022-01-012022-09-300001651311mrus:SecondONOResearchAndLicenseAgreementMember2018-03-142018-03-140001651311mrus:MarketableSecuritiesNonCurrentMember2022-09-300001651311us-gaap:OtherIncomeMember2022-01-012022-03-310001651311mrus:LillyCollaborationsAgreementMember2021-01-182021-01-180001651311us-gaap:RetainedEarningsMember2021-12-310001651311mrus:PublicOfferingsNetOfUnderwritingDiscountsAndCommissionsAndOfferingCostMember2022-04-012022-06-300001651311us-gaap:RetainedEarningsMember2022-07-012022-09-300001651311us-gaap:ResearchAndDevelopmentExpenseMember2022-07-012022-09-300001651311mrus:IncyteMemberus-gaap:AccountsReceivableMember2022-01-012022-09-300001651311mrus:OtherMember2022-07-012022-09-300001651311mrus:LillyCollaborationsAgreementMember2021-02-120001651311us-gaap:CommonStockMember2021-06-300001651311us-gaap:MoneyMarketFundsMember2021-12-3100016513112021-01-012021-03-310001651311mrus:SalesAgreementMember2022-01-012022-09-300001651311us-gaap:CommonStockMember2021-01-012021-03-310001651311mrus:SimcereCollaborationAndLicenseAgreementMember2018-01-310001651311us-gaap:TaxAndCustomsAdministrationNetherlandsMember2022-01-012022-09-300001651311us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-09-300001651311us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember2021-12-310001651311mrus:DeferredRevenueMembermrus:LillyMember2021-12-3100016513112021-06-300001651311us-gaap:USTreasurySecuritiesMember2022-09-300001651311mrus:IncyteMember2021-07-012021-09-300001651311us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-09-300001651311us-gaap:RetainedEarningsMember2021-01-012021-03-310001651311mrus:LillyMember2021-07-012021-09-300001651311mrus:CollaborationRevenueMember2022-01-012022-09-300001651311us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-300001651311us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-04-012021-06-300001651311us-gaap:OtherAssetsMember2022-09-300001651311mrus:MarketableSecuritiesCurrentMember2021-12-310001651311mrus:SalesAgreementMember2022-09-300001651311us-gaap:AdditionalPaidInCapitalMembermrus:LillyMember2021-01-012021-03-3100016513112020-01-012020-12-310001651311us-gaap:CommonStockMember2022-06-3000016513112020-12-310001651311us-gaap:AdditionalPaidInCapitalMember2021-06-300001651311mrus:LillyMember2021-01-012021-03-310001651311us-gaap:AccountsReceivableMembermrus:CollaborationAgreementMember2021-12-310001651311srt:MaximumMembermrus:SalesAgreementMember2021-05-3100016513112022-07-012022-09-300001651311mrus:OfficeAndLaboratoryMembermrus:KadansSciencePartnerXIIBVMember2022-04-050001651311us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-09-300001651311mrus:CollaborationRevenueMember2021-01-012021-09-300001651311us-gaap:CommonStockMember2022-01-012022-03-3100016513112022-03-310001651311us-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-12-310001651311us-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-300001651311us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001651311us-gaap:AdditionalPaidInCapitalMember2021-12-3100016513112022-09-3000016513112022-04-012022-06-300001651311us-gaap:GeneralAndAdministrativeExpenseMember2021-07-012021-09-300001651311us-gaap:ResearchAndDevelopmentExpenseMember2021-07-012021-09-300001651311us-gaap:AdditionalPaidInCapitalMember2022-09-300001651311mrus:MerusNVMembermrus:IncyteMember2022-09-300001651311mrus:UnbilledReceivablesMembermrus:CollaborationAgreementMember2022-01-012022-09-300001651311us-gaap:MoneyMarketFundsMember2022-09-300001651311mrus:PublicOfferingsNetOfUnderwritingDiscountsAndCommissionsAndOfferingCostMember2022-07-012022-09-300001651311us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-3100016513112021-01-012021-09-300001651311us-gaap:AdditionalPaidInCapitalMember2022-06-300001651311mrus:LillyCollaborationsAgreementMember2021-01-180001651311us-gaap:CommonStockMembermrus:LillyMember2021-01-012021-03-3100016513112021-12-310001651311us-gaap:CommonStockMember2021-09-300001651311us-gaap:RetainedEarningsMember2022-06-300001651311us-gaap:CommonStockMember2022-04-012022-06-300001651311us-gaap:RetainedEarningsMember2022-04-012022-06-300001651311us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember2022-09-300001651311us-gaap:CommonStockMember2020-12-310001651311us-gaap:CashEquivalentsMember2021-12-310001651311mrus:MarketableSecuritiesNonCurrentMember2021-12-310001651311mrus:DeferredRevenueMembermrus:CollaborationAgreementMember2022-09-300001651311mrus:UnbilledReceivablesMembermrus:OtherMember2022-09-300001651311us-gaap:RetainedEarningsMember2020-12-310001651311us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310001651311mrus:DeferredRevenueMembermrus:IncyteMember2022-09-300001651311mrus:CorporatePaperNotesAndBondsMember2022-09-300001651311mrus:OtherMember2021-01-012021-09-300001651311us-gaap:RetainedEarningsMember2021-03-310001651311mrus:DeferredRevenueMembermrus:OtherMember2022-01-012022-09-300001651311mrus:LillyCollaborationsAgreementMember2022-07-012022-09-300001651311mrus:DeferredRevenueMembermrus:CollaborationAgreementMember2022-01-012022-09-300001651311mrus:OfficeAndLaboratoryMembermrus:KadansSciencePartnerXIIBVMember2022-04-012022-04-300001651311us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-07-012021-09-300001651311mrus:CollaborationAgreementMember2021-07-012021-09-300001651311mrus:IncyteCollaborationAndLicenseAgreementMembermrus:LicenseAndRelatedActivitiesMember2017-01-232017-01-230001651311us-gaap:GeneralAndAdministrativeExpenseMember2022-07-012022-09-300001651311mrus:OtherMember2021-07-012021-09-300001651311mrus:OfficeAndLaboratoryMembermrus:KadansSciencePartnerXIIBVMember2022-09-300001651311us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300001651311mrus:LillyCollaborationMember2021-01-012021-09-300001651311mrus:IncyteMember2022-01-012022-09-300001651311mrus:DeferredRevenueMembermrus:IncyteMember2021-12-310001651311us-gaap:AdditionalPaidInCapitalMember2021-09-300001651311mrus:DeferredRevenueMembermrus:LillyMember2022-01-012022-09-300001651311mrus:DeferredRevenueMembermrus:OtherMember2021-12-310001651311mrus:UnbilledReceivablesMembermrus:IncyteMember2021-12-310001651311us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001651311mrus:LillyCollaborationMember2022-01-012022-09-300001651311us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300001651311mrus:LillyMembermrus:UnbilledReceivablesMember2021-12-310001651311us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-09-300001651311srt:MaximumMemberus-gaap:TaxAndCustomsAdministrationNetherlandsMember2022-01-012022-09-300001651311mrus:OtherMemberus-gaap:AccountsReceivableMember2021-12-310001651311us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-300001651311mrus:DeferredRevenueMembermrus:IncyteMember2022-01-012022-09-3000016513112021-04-012021-06-300001651311mrus:CorporatePaperNotesAndBondsMember2021-12-310001651311us-gaap:AdditionalPaidInCapitalMembermrus:PublicOfferingsNetOfUnderwritingDiscountsAndCommissionsAndOfferingCostMember2022-04-012022-06-300001651311us-gaap:CommonStockMember2022-07-012022-09-3000016513112022-06-300001651311us-gaap:RetainedEarningsMember2021-04-012021-06-300001651311us-gaap:CashEquivalentsMember2022-09-300001651311mrus:UnbilledReceivablesMembermrus:OtherMember2022-01-012022-09-300001651311mrus:PublicOfferingsNetOfUnderwritingDiscountsAndCommissionsAndOfferingCostMemberus-gaap:CommonStockMember2022-04-012022-06-300001651311mrus:LillyMember2022-07-012022-09-300001651311mrus:UnbilledReceivablesMembermrus:OtherMember2021-12-310001651311mrus:PublicOfferingsNetOfUnderwritingDiscountsAndCommissionsAndOfferingCostMemberus-gaap:CommonStockMember2022-07-012022-09-300001651311mrus:CollaborationAgreementMember2022-07-012022-09-300001651311us-gaap:RetainedEarningsMember2021-07-012021-09-300001651311us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-09-300001651311mrus:UnbilledReceivablesMembermrus:CollaborationAgreementMember2022-09-300001651311mrus:UnbilledReceivablesMembermrus:IncyteMember2022-09-300001651311us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-3100016513112022-11-010001651311us-gaap:AdditionalPaidInCapitalMembermrus:PublicOfferingsNetOfUnderwritingDiscountsAndCommissionsAndOfferingCostMember2022-07-012022-09-300001651311us-gaap:CommonStockMember2021-07-012021-09-300001651311us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300001651311mrus:SimcereCollaborationAndLicenseAgreementMember2018-01-012018-01-310001651311mrus:CollaborationRevenueRelatedPartyMember2021-01-012021-09-300001651311mrus:CollaborationRevenueRelatedPartyMember2022-01-012022-09-300001651311mrus:SecondONOResearchAndLicenseAgreementMember2018-03-140001651311mrus:UnbilledReceivablesMembermrus:CollaborationAgreementMember2021-12-310001651311us-gaap:RetainedEarningsMember2021-09-3000016513112021-07-012021-09-300001651311mrus:UnbilledReceivablesMembermrus:LillyMember2022-01-012022-09-300001651311mrus:IncyteMemberus-gaap:AccountsReceivableMember2021-12-3100016513112021-03-310001651311mrus:DeferredRevenueMembermrus:LillyMember2022-09-300001651311mrus:SimcereCollaborationAndLicenseAgreementMember2018-08-312018-08-310001651311mrus:LicenseAndPerformanceMemberus-gaap:ResearchAndDevelopmentArrangementMembermrus:SimcereCollaborationAndLicenseAgreementMember2018-01-012018-01-310001651311mrus:CollaborationAgreementMember2021-01-012021-09-300001651311mrus:LillyMemberus-gaap:AccountsReceivableMember2022-01-012022-09-3000016513112021-09-300001651311us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310001651311us-gaap:AdditionalPaidInCapitalMember2020-12-310001651311us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-300001651311us-gaap:CommonStockMember2021-04-012021-06-300001651311us-gaap:CommonStockMember2022-09-30iso4217:USDxbrli:sharesiso4217:EURutr:sqmxbrli:pureiso4217:EURxbrli:sharesxbrli:sharesmrus:Antibodymrus:PerformanceObligationmrus:Renewaltermiso4217:USDmrus:Milestone

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2022

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 001-37773

 

MERUS N.V.

(Exact name of registrant as specified in its charter)

 

 

The Netherlands

Not Applicable

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

 

Yalelaan 62

3584 CM Utrecht

The Netherlands

Not Applicable

(Address of principal executive offices)

(Zip code)

 

+31 85 016 2500

(Registrant’s telephone number, including area code)

 

 

N/A

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading symbol(s)

Name of each exchange on which registered

Common shares, nominal value €0.09 per share

MRUS

The Nasdaq Stock Market LLC

(Nasdaq Global Market)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

 

Accelerated filer

 

 

 

 

 

 

Non-accelerated filer

 

 

Smaller reporting company

 

 

 

 

 

 

 

 

 

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act).

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

 

As of November 1, 2022, the registrant had 46,302,877 common shares, nominal value €0.09 per share, outstanding.

 

 


 

 

PART I — FINANCIAL INFORMATION

 

 

 

Item 1. Financial Statements

2

 

 

Condensed Consolidated Balance Sheets
as of September 30, 2022 and December 31, 2021

2

 

 

Condensed Consolidated Statements of Operations and Comprehensive Loss
for the three and nine months ended September 30, 2022 and 2021

3

 

 

Condensed Consolidated Statements of Cash Flows
for the nine months ended September 30, 2022 and 2021

4

 

 

Condensed Consolidated Statements of Changes in Stockholders’ Equity
for the three and nine months ended September 30, 2022 and 2021

5

 

 

Notes to Condensed Consolidated Financial Statements

6

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

16

 

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk

24

 

 

Item 4. Controls and Procedures

24

 

 

PART II — OTHER INFORMATION

 

 

 

Item 1. Legal Proceedings

26

 

 

Item 1A. Risk Factors

26

 

 

Item 5. Other Information

72

 

 

Item 6. Exhibits

72

 

 

Signatures

73

 

 


 

Cautionary Note Regarding Forward-looking Statements

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. All statements other than statements of historical fact contained in this Quarterly Report on Form 10-Q, including without limitation statements regarding our plans to develop and commercialize our product candidates, the timing of our ongoing or planned clinical trials, the timing of and our ability to obtain and maintain regulatory approvals, the anticipated impact of the COVID-19 pandemic on our business and operations, the clinical utility and commercial potential of our product candidates, our commercialization, marketing and manufacturing capabilities and strategy, our expectations surrounding our collaborations, our expectations about the willingness of healthcare professionals to use our product candidates, the sufficiency of our cash, cash equivalents and investments, and the plans and objectives of management for future operations and capital expenditures are forward-looking statements.

The forward-looking statements in this Quarterly Report on Form 10-Q are only predictions and are based largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and are subject to a number of known and unknown risks, uncertainties, assumptions and other important factors, including those described under the sections in this Quarterly Report on Form 10-Q entitled “Summary Risk Factors,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in this Quarterly Report on Form 10-Q.

Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

 

SUMMARY RISK FACTORS

Our business is subject to numerous risks and uncertainties, including those described in Part II, Item 1A. “Risk Factors” in this Quarterly Report on Form 10-Q. You should carefully consider these risks and uncertainties when investing in our common shares. The principal risks and uncertainties affecting our business include the following:

 

We have incurred significant net losses since our inception and we expect to continue to incur significant expenses and operating losses for the foreseeable future.
We have a limited operating history, have not completed any registrational clinical trials, and have no products approved for commercial sale, which may make it difficult for you to evaluate our current business and predict our future success and viability.
We will require substantial additional capital to finance our operations. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce or eliminate one or more of our research and drug development programs or future commercialization efforts.
The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and the results of our clinical trials may not satisfy the requirements of the FDA, EMA or other comparable foreign regulatory authorities.
The clinical trial and regulatory approval processes are lengthy, time consuming and inherently unpredictable, and we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.
Our antibody candidates may have serious adverse, undesirable or unacceptable side effects which may delay or prevent marketing approval. If such side effects are identified during the development of our antibody candidates or following approval, if any, we may need to abandon our development of such antibody candidates, the commercial profile of any

 


 

approved label may be limited, or we may be subject to other significant negative consequences following marketing approval, if any.
We have never commercialized an antibody candidate before and may lack the necessary expertise, personnel and resources to successfully commercialize our products on our own or together with suitable collaborators.
We rely, and expect to continue to rely, on third parties, including independent clinical investigators and contract research organizations or CROs, to conduct our pre-clinical studies, clinical trials, chemistry, manufacturing and controls and potential development of a companion diagnostic. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our antibody candidates or we may be subject to other significant negative consequences following marketing approval, if any and our business could be substantially harmed.
Due to our limited resources and access to capital, we must, and have in the past decided to, prioritize development of certain antibody candidates over other potential candidates. These decisions may prove to have been wrong and may adversely affect our revenues.
The competition for qualified personnel is particularly intense in our industry. If we are unable to retain or hire key personnel, we may not be able to sustain or grow our business.
We operate in highly competitive and rapidly changing industries, and if our competitors develop and market technologies or products more rapidly than we do or that are more effective, safer or less expensive than the product candidates we develop, our commercial opportunities will be negatively impacted.
Our success depends on our ability to protect our intellectual property and our proprietary technologies. If we are unable to adequately protect our intellectual property and our proprietary technologies or obtain and maintain issued patents which are sufficient to protect our product candidates and proprietary technologies, or if others do not respect our intellectual property rights and exclusivity, others could compete against us more directly, which would negatively impact our business.
Our existing collaborations are important to our business and future licenses may also be important to us, and if we are unable to maintain any of these collaborations, or if these arrangements are not successful, our business could be adversely affected.
The COVID-19 pandemic caused by the novel coronavirus has and may continue to adversely impact our business, including our pre-clinical studies and clinical trials, financial condition and results of operations.

 

 

 


 

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements

MERUS N.V.

CONDENSED CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

(Amounts in thousands, except per share data)

 

 

 

September 30,
2022

 

 

December 31,
2021

 

ASSETS

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

190,980

 

 

$

241,435

 

Marketable securities

 

 

160,463

 

 

 

168,990

 

Accounts receivable

 

 

2,628

 

 

 

1,697

 

Accounts receivable (related party)

 

 

 

 

 

4,609

 

Prepaid expenses and other current assets

 

 

14,128

 

 

 

7,448

 

Total current assets

 

 

368,199

 

 

 

424,179

 

Marketable securities

 

 

21,476

 

 

 

20,297

 

Property and equipment, net

 

 

7,339

 

 

 

3,549

 

Operating lease right-of-use assets

 

 

12,345

 

 

 

3,733

 

Intangible assets, net

 

 

1,889

 

 

 

2,347

 

Deferred tax assets

 

 

435

 

 

 

417

 

Other assets

 

 

3,307

 

 

 

2,078

 

Total assets

 

$

414,990

 

 

$

456,600

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

3,117

 

 

$

13,237

 

Accrued expenses and other liabilities

 

 

31,190

 

 

 

22,506

 

Income taxes payable

 

 

 

 

 

 

Current portion of lease obligation

 

 

1,868

 

 

 

1,494

 

Current portion of deferred revenue

 

 

27,975

 

 

 

16,613

 

Current portion of deferred revenue (related party)

 

 

 

 

 

18,048

 

Total current liabilities

 

 

64,150

 

 

 

71,898

 

Lease obligation

 

 

11,273

 

 

 

2,257

 

Deferred revenue, net of current portion

 

 

40,790

 

 

 

10,962

 

Deferred revenue, net of current portion (related party)

 

 

 

 

 

55,282

 

Total liabilities

 

 

116,213

 

 

 

140,399

 

Commitments and contingencies - Note 6

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

Common shares, €0.09 par value; 67,500,000 shares authorized as at September 30, 2022 and December 31, 2021;
46,302,877 and 43,467,052 shares issued and outstanding as at
September 30, 2022 and December 31, 2021, respectively

 

 

4,750

 

 

 

4,481

 

Additional paid-in capital

 

 

864,842

 

 

 

787,869

 

Accumulated other comprehensive income

 

 

(54,665

)

 

 

(9,221

)

Accumulated deficit

 

 

(516,150

)

 

 

(466,928

)

Total stockholders’ equity

 

 

298,777

 

 

 

316,201

 

Total liabilities and stockholders’ equity

 

$

414,990

 

 

$

456,600

 

 

See accompanying notes to the Unaudited Condensed Consolidated Financial Statements.

2


 

MERUS N.V.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(UNAUDITED)

(Amounts in thousands, except per share data)

 

 

 

Three Months Ended
September 30,

 

 

Nine Months Ended
September 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Collaboration revenue

 

$

6,581

 

 

$

5,919

 

 

$

30,920

 

 

$

12,636

 

Collaboration revenue (related party)

 

 

 

 

 

7,750

 

 

 

 

 

 

21,762

 

Total revenue

 

 

6,581

 

 

 

13,669

 

 

 

30,920

 

 

 

34,398

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

 

42,307

 

 

 

26,018

 

 

 

100,378

 

 

 

71,436

 

General and administrative

 

 

12,469

 

 

 

10,171

 

 

 

36,917

 

 

 

30,073

 

Total operating expenses

 

 

54,776

 

 

 

36,189

 

 

 

137,295

 

 

 

101,509

 

Operating loss

 

 

(48,195

)

 

 

(22,520

)

 

 

(106,375

)

 

 

(67,111

)

Other (loss) income, net:

 

 

 

 

 

 

 

 

 

 

 

 

Interest (expense) income, net

 

 

866

 

 

 

(25

)

 

 

1,288

 

 

 

(158

)

Foreign exchange gains (loss)

 

 

23,041

 

 

 

7,756

 

 

 

55,378

 

 

 

15,434

 

Other (losses) gains, net

 

 

 

 

 

(75

)

 

 

1,059

 

 

 

(460

)

Total other income (loss), net

 

 

23,907

 

 

 

7,656

 

 

 

57,725

 

 

 

14,816

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss before income taxes

 

 

(24,288

)

 

 

(14,864

)

 

 

(48,650

)

 

 

(52,295

)

Income tax expense

 

 

327

 

 

 

(11

)

 

 

572

 

 

 

100

 

Net loss

 

$

(24,615

)

 

$

(14,853

)

 

$

(49,222

)

 

$

(52,395

)

Other comprehensive loss:

 

 

 

 

 

 

 

 

 

 

 

 

Currency translation adjustment

 

 

(19,475

)

 

 

(5,391

)

 

 

(45,444

)

 

 

(11,307

)

Comprehensive loss

 

$

(44,090

)

 

$

(20,244

)

 

$

(94,666

)

 

$

(63,702

)

Net loss per share attributable to common stockholders:
      Basic and diluted

 

$

(0.53

)

 

$

(0.39

)

 

$

(1.11

)

 

$

(1.39

)

Weighted-average common shares outstanding:
      Basic and diluted

 

 

46,057

 

 

 

38,513

 

 

 

44,452

 

 

 

37,708

 

 

See accompanying notes to the Unaudited Condensed Consolidated Financial Statements.

3


 

MERUS N.V.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

(Amounts in thousands)

 

 

 

Nine Months Ended
September 30,

 

 

 

2022

 

 

2021

 

CASH FLOWS FROM OPERATING ACTIVITIES:

 

 

 

 

 

 

Net loss

 

$

(49,222

)

 

$

(52,395

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

Depreciation and amortization of property and equipment

 

 

778

 

 

 

946

 

Amortization of intangible assets

 

 

195

 

 

 

219

 

Foreign exchange gain

 

 

(68,654

)

 

 

(14,181

)

Stock-based compensation expense

 

 

18,521

 

 

 

12,290

 

Amortization of discount on investments

 

 

243

 

 

 

139

 

Deferred tax expense

 

 

(19

)

 

 

190

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

Accounts receivable

 

 

3,031

 

 

 

(1,718

)

Operating lease right-of-use assets and lease obligations

 

 

846

 

 

 

(32

)

Prepaid expenses and other current assets

 

 

(8,987

)

 

 

(2,477

)

Accounts payable

 

 

(9,067

)

 

 

2,567

 

Accrued expenses and other liabilities

 

 

12,514

 

 

 

6,931

 

Deferred revenue

 

 

(19,566

)

 

 

19,492

 

Net cash provided by (used in) operating activities

 

 

(119,387

)

 

 

(28,029

)

CASH FLOWS FROM INVESTING ACTIVITIES:

 

 

 

 

 

 

Purchases of marketable securities

 

 

(170,692

)

 

 

(204,456

)

Proceeds from maturities of marketable securities

 

 

178,169

 

 

 

74,129

 

Purchases of property and equipment

 

 

(5,531

)

 

 

(537

)

Net cash provided by (used in) investing activities

 

 

1,946

 

 

 

(130,864

)

CASH FLOWS FROM FINANCING ACTIVITIES:

 

 

 

 

 

 

Proceeds from issuance of common stock, net

 

 

57,741

 

 

 

129,398

 

Proceeds from issuance of common stock - Lilly

 

 

 

 

 

16,477

 

Proceeds from stock options exercised

 

 

1,213

 

 

 

9,041

 

Repurchase of restricted stock units

 

 

 

 

 

(285

)

Short-swing profit disgorgement

 

 

 

 

 

282

 

Net cash provided by financing activities

 

 

58,954

 

 

 

154,913

 

Foreign exchange impact on cash, cash equivalents and restricted cash

 

 

8,866

 

 

 

19

 

Net increase (decrease) in cash, cash equivalents and restricted cash

 

 

(49,621

)

 

 

(3,961

)

Cash, cash equivalents, and restricted cash, beginning of period

 

 

241,749

 

 

 

163,283

 

Cash, cash equivalents, and restricted cash, end of period

 

$

192,128

 

 

$

159,322

 

SUPPLEMENTAL DISCLOSURES:

 

 

 

 

 

 

Lease liabilities arising from obtaining right-of-use assets

 

$

11,493

 

 

$

1,662

 

Income taxes paid

 

$

 

 

$

621

 

Non-cash purchases of property, equipment and intangibles

 

$

2

 

 

$

 

Non-cash issuance of stock options

 

$

 

 

$

573

 

CASH, CASH EQUIVALENTS AND RESTRICTED CASH

 

 

 

 

 

 

Cash and cash equivalents

 

$

190,980

 

 

$

159,121

 

Restricted cash included in non-current other assets

 

 

1,148

 

 

 

201

 

 

 

$

192,128

 

 

$

159,322

 

 

See accompanying notes to the Condensed Consolidated Financial Statements.

4


 

MERUS N.V.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

(UNAUDITED)

(Amounts in thousands, except share amounts)

 

 

 

Common Stock

 

 

Additional
Paid-In

 

 

Accumulated

 

 

Accumulated
Other
Comprehensive

 

 

Total
Stockholders’

 

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Deficit

 

 

Income (Loss)

 

 

Equity

 

Balance at January 1, 2021

 

 

31,602,953

 

 

$

3,211

 

 

$

490,093

 

 

$

(400,112

)

 

$

9,071

 

 

$

102,263

 

Issuance of common stock, net

 

 

5,575,757

 

 

 

610

 

 

 

128,793

 

 

 

 

 

 

 

 

 

129,403

 

Issuance of common stock - Lilly

 

 

706,834

 

 

 

77

 

 

 

16,400

 

 

 

 

 

 

 

 

 

16,477

 

Exercise of stock options and vesting of restricted stock units

 

 

386,097

 

 

 

42

 

 

 

4,782

 

 

 

 

 

 

 

 

 

4,824

 

Repurchase of restricted stock units

 

 

 

 

 

 

 

 

(285

)

 

 

 

 

 

 

 

 

(285

)

Stock-based compensation

 

 

 

 

 

 

 

 

3,400

 

 

 

 

 

 

 

 

 

3,400

 

Currency translation adjustment

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(9,391

)

 

 

(9,391

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

(10,154

)

 

 

 

 

 

(10,154

)

Balance at March 31, 2021

 

 

38,271,641

 

 

$

3,940

 

 

$

643,183

 

 

$

(410,266

)

 

$

(320

)

 

$

236,537

 

Exercise of stock options and vesting of restricted stock units

 

 

172,939

 

 

 

19

 

 

 

1,885

 

 

 

 

 

 

 

 

 

1,904

 

Stock-based compensation

 

 

 

 

 

 

 

 

4,559

 

 

 

 

 

 

 

 

 

4,559

 

Currency translation adjustment

 

 

 

 

 

 

 

 

 

 

 

 

 

 

3,475

 

 

 

3,475

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

(27,388

)

 

 

 

 

 

(27,388

)

Balance at June 30, 2021

 

 

38,444,580

 

 

$

3,959

 

 

$

649,627

 

 

$

(437,654

)

 

$

3,155

 

 

$

219,087

 

Exercise of stock options and vesting of restricted stock units

 

 

160,516

 

 

 

17

 

 

 

2,296

 

 

 

 

 

 

 

 

 

2,313

 

Short-swing profit disgorgement

 

 

 

 

 

 

 

 

282

 

 

 

 

 

 

 

 

 

282

 

Stock-based compensation

 

 

 

 

 

 

 

 

4,331

 

 

 

 

 

 

 

 

 

4,331

 

Currency translation adjustment

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(5,391

)

 

 

(5,391

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

(14,853

)

 

 

 

 

 

(14,853

)

Balance at September 30, 2021